Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Aug 1;98(3):671–679. doi: 10.1172/JCI118838

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

O V Volpert 1, W F Ward 1, M W Lingen 1, L Chesler 1, D B Solt 1, M D Johnson 1, A Molteni 1, P J Polverini 1, N P Bouck 1
PMCID: PMC507476  PMID: 8698858

Abstract

Captopril, an inhibitor of angiotensin converting enzyme, is widely used clinically to manage hypertension and congestive heart failure. Here captopril is shown to be an inhibitor of angiogenesis able to block neovascularization induced in the rat cornea. Captopril acted directly and specifically on capillary endothelial cells, inhibiting their chemotaxis with a biphasic dose-response curve showing an initial decrease at clinically achievable doses under 10 microM and a further slow decline in the millimolar range. Captopril inhibition of endothelial cell migration was not mediated by angiotensin converting enzyme inhibition, but was suppressed by zinc. Direct inhibition by captopril of zinc-dependent endothelial cell-derived 72-and 92-kD metalloproteinases known to be essential for angiogenesis was also seen. When used systemically on rats captopril inhibited corneal neovascularization and showed the antitumor activity expected of an inhibitor of angiogenesis, decreasing the number of mitoses present in carcinogen-induced foci of preneoplastic liver cells and slowing the growth rate of an experimental fibrosarcoma whose cells were resistant to captopril in vitro. These data define this widely used drug as a new inhibitor of neovascularization and raise the possibility that patients on long term captopril therapy may derive unexpected benefits from its antiangiogenic activities.

Full Text

The Full Text of this article is available as a PDF (394.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahn K., Pan S., Beningo K., Hupe D. A permanent human cell line (EA.hy926) preserves the characteristics of endothelin converting enzyme from primary human umbilical vein endothelial cells. Life Sci. 1995;56(26):2331–2341. doi: 10.1016/0024-3205(95)00227-w. [DOI] [PubMed] [Google Scholar]
  2. Ashab I., Peer G., Blum M., Wollman Y., Chernihovsky T., Hassner A., Schwartz D., Cabili S., Silverberg D., Iaina A. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int. 1995 Jun;47(6):1515–1521. doi: 10.1038/ki.1995.214. [DOI] [PubMed] [Google Scholar]
  3. Bell L., Luthringer D. J., Madri J. A., Warren S. L. Autocrine angiotensin system regulation of bovine aortic endothelial cell migration and plasminogen activator involves modulation of proto-oncogene pp60c-src expression. J Clin Invest. 1992 Jan;89(1):315–320. doi: 10.1172/JCI115578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bell L., Madri J. A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990 Jul;137(1):7–12. [PMC free article] [PubMed] [Google Scholar]
  5. Bouck N., Stellmach V., Hsu S. C. How tumors become angiogenic. Adv Cancer Res. 1996;69:135–174. doi: 10.1016/s0065-230x(08)60862-3. [DOI] [PubMed] [Google Scholar]
  6. Burris J. F. The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J Clin Pharmacol. 1995 Apr;35(4):337–342. doi: 10.1002/j.1552-4604.1995.tb04070.x. [DOI] [PubMed] [Google Scholar]
  7. Chobanian A. V., Haudenschild C. C., Nickerson C., Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990 Mar;15(3):327–331. doi: 10.1161/01.hyp.15.3.327. [DOI] [PubMed] [Google Scholar]
  8. Duchin K. L., McKinstry D. N., Cohen A. I., Migdalof B. H. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin Pharmacokinet. 1988 Apr;14(4):241–259. doi: 10.2165/00003088-198814040-00002. [DOI] [PubMed] [Google Scholar]
  9. Emoto N., Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem. 1995 Jun 23;270(25):15262–15268. doi: 10.1074/jbc.270.25.15262. [DOI] [PubMed] [Google Scholar]
  10. Fernandez L. A., Twickler J., Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med. 1985 Feb;105(2):141–145. [PubMed] [Google Scholar]
  11. Fisher C., Gilbertson-Beadling S., Powers E. A., Petzold G., Poorman R., Mitchell M. A. Interstitial collagenase is required for angiogenesis in vitro. Dev Biol. 1994 Apr;162(2):499–510. doi: 10.1006/dbio.1994.1104. [DOI] [PubMed] [Google Scholar]
  12. Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987 Jan 23;235(4787):442–447. doi: 10.1126/science.2432664. [DOI] [PubMed] [Google Scholar]
  13. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990 Jan 3;82(1):4–6. doi: 10.1093/jnci/82.1.4. [DOI] [PubMed] [Google Scholar]
  14. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995 May 10;273(18):1450–1456. [PubMed] [Google Scholar]
  15. Guest I., Buttar H. S., Smith S., Varma D. R. Evaluation of the rat embryo culture system as a predictive test for human teratogens. Can J Physiol Pharmacol. 1994 Jan;72(1):57–62. doi: 10.1139/y94-010. [DOI] [PubMed] [Google Scholar]
  16. Guivernau M., Armijo F., Rosas R. Role of sulfhydryl groups in the stimulatory effect of captopril on vascular prostacyclin synthesis. Eur J Pharmacol. 1991 May 30;198(1):1–6. doi: 10.1016/0014-2999(91)90554-4. [DOI] [PubMed] [Google Scholar]
  17. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995 Mar 18;345(8951):669–685. [PubMed] [Google Scholar]
  18. Jackson W. E., Holmes D. L., Garg S. K., Harris S., Chase H. P. Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann Ophthalmol. 1992 Mar;24(3):99–103. [PubMed] [Google Scholar]
  19. Kohama Y., Oka H., Murayama N., Iida K., Itoh M., Itoh M., Ying X., Mimura T. Increase of migration of cultured endothelial cells by angiotensin-converting enzyme inhibitor derived from tuna muscle. J Pharmacobiodyn. 1992 May;15(5):223–229. doi: 10.1248/bpb1978.15.223. [DOI] [PubMed] [Google Scholar]
  20. Kreft-Jais C., Plouin P. F., Tchobroutsky C., Boutroy M. J. Angiotensin-converting enzyme inhibitors during pregnancy: a survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynaecol. 1988 Apr;95(4):420–422. doi: 10.1111/j.1471-0528.1988.tb06619.x. [DOI] [PubMed] [Google Scholar]
  21. Le Noble F. A., Hekking J. W., Van Straaten H. W., Slaaf D. W., Struyker Boudier H. A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol. 1991 Mar 26;195(2):305–306. doi: 10.1016/0014-2999(91)90552-2. [DOI] [PubMed] [Google Scholar]
  22. Le Noble F. A., Schreurs N. H., van Straaten H. W., Slaaf D. W., Smits J. F., Rogg H., Struijker-Boudier H. A. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol. 1993 Feb;264(2 Pt 2):R460–R465. doi: 10.1152/ajpregu.1993.264.2.R460. [DOI] [PubMed] [Google Scholar]
  23. Lewis E. J. Captopril and diabetic nephropathy. JAMA. 1995 Jun 21;273(23):1831–1831. [PubMed] [Google Scholar]
  24. Liotta L. A., Tryggvason K., Garbisa S., Robey P. G., Abe S. Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry. 1981 Jan 6;20(1):100–104. doi: 10.1021/bi00504a017. [DOI] [PubMed] [Google Scholar]
  25. Mansfield P. J., Boxer L. A., Suchard S. J. Thrombospondin stimulates motility of human neutrophils. J Cell Biol. 1990 Dec;111(6 Pt 2):3077–3086. doi: 10.1083/jcb.111.6.3077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Martin M. F., Surrall K. E., McKenna F., Dixon J. S., Bird H. A., Wright V. Captopril: a new treatment for rheumatoid arthritis? Lancet. 1984 Jun 16;1(8390):1325–1328. doi: 10.1016/s0140-6736(84)91821-x. [DOI] [PubMed] [Google Scholar]
  27. Materson B. J., Preston R. A. Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience. Arch Intern Med. 1994 Mar 14;154(5):513–523. [PubMed] [Google Scholar]
  28. Matsubara T., Saura R., Hirohata K., Ziff M. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest. 1989 Jan;83(1):158–167. doi: 10.1172/JCI113853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Migdalof B. H., Antonaccio M. J., McKinstry D. N., Singhvi S. M., Lan S. J., Egli P., Kripalani K. J. Captopril: pharmacology, metabolism and disposition. Drug Metab Rev. 1984;15(4):841–869. doi: 10.3109/03602538409041080. [DOI] [PubMed] [Google Scholar]
  30. Moses M. A., Sudhalter J., Langer R. Identification of an inhibitor of neovascularization from cartilage. Science. 1990 Jun 15;248(4961):1408–1410. doi: 10.1126/science.1694043. [DOI] [PubMed] [Google Scholar]
  31. Moses M. A., Sudhalter J., Langer R. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol. 1992 Oct;119(2):475–482. doi: 10.1083/jcb.119.2.475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Murphy A. N., Unsworth E. J., Stetler-Stevenson W. G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol. 1993 Nov;157(2):351–358. doi: 10.1002/jcp.1041570219. [DOI] [PubMed] [Google Scholar]
  33. Orning L., Krivi G., Bild G., Gierse J., Aykent S., Fitzpatrick F. A. Inhibition of leukotriene A4 hydrolase/aminopeptidase by captopril. J Biol Chem. 1991 Sep 5;266(25):16507–16511. [PubMed] [Google Scholar]
  34. Palatini P., Dabbeni-Sala F., Finotti P. Inhibition of dopamine beta-hydroxylase by captopril. Biochem Pharmacol. 1989 Mar 15;38(6):1011–1013. doi: 10.1016/0006-2952(89)90293-1. [DOI] [PubMed] [Google Scholar]
  35. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  36. Polverini P. J., Bouck N. P., Rastinejad F. Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol. 1991;198:440–450. doi: 10.1016/0076-6879(91)98044-7. [DOI] [PubMed] [Google Scholar]
  37. Polverini P. J., Leibovich S. J. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest. 1984 Dec;51(6):635–642. [PubMed] [Google Scholar]
  38. Sorbi D., Fadly M., Hicks R., Alexander S., Arbeit L. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int. 1993 Dec;44(6):1266–1272. doi: 10.1038/ki.1993.378. [DOI] [PubMed] [Google Scholar]
  39. Takahashi M., Matsushita Y., Iijima Y., Tanzawa K. Purification and characterization of endothelin-converting enzyme from rat lung. J Biol Chem. 1993 Oct 5;268(28):21394–21398. [PubMed] [Google Scholar]
  40. Takigawa M., Nishida Y., Suzuki F., Kishi J., Yamashita K., Hayakawa T. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem Biophys Res Commun. 1990 Sep 28;171(3):1264–1271. doi: 10.1016/0006-291x(90)90822-5. [DOI] [PubMed] [Google Scholar]
  41. Tannock I. F. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res. 1970 Oct;30(10):2470–2476. [PubMed] [Google Scholar]
  42. Tolsma S. S., Volpert O. V., Good D. J., Frazier W. A., Polverini P. J., Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol. 1993 Jul;122(2):497–511. doi: 10.1083/jcb.122.2.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Tsuboi R., Sato Y., Rifkin D. B. Correlation of cell migration, cell invasion, receptor number, proteinase production, and basic fibroblast growth factor levels in endothelial cells. J Cell Biol. 1990 Feb;110(2):511–517. doi: 10.1083/jcb.110.2.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wang D. H., Prewitt R. L. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension. 1990 Jan;15(1):68–77. doi: 10.1161/01.hyp.15.1.68. [DOI] [PubMed] [Google Scholar]
  45. Ward W. F., Kim Y. T., Molteni A., Solliday N. H. Radiation-induced pulmonary endothelial dysfunction in rats: modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys. 1988 Jul;15(1):135–140. doi: 10.1016/0360-3016(88)90357-4. [DOI] [PubMed] [Google Scholar]
  46. Ward W. F., Molteni A., Ts'ao C., Hinz J. M. The effect of Captopril on benign and malignant reactions in irradiated rat skin. Br J Radiol. 1990 May;63(749):349–354. doi: 10.1259/0007-1285-63-749-349. [DOI] [PubMed] [Google Scholar]
  47. Warren J. B., Loi R. K. Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins. FASEB J. 1995 Mar;9(5):411–418. doi: 10.1096/fasebj.9.5.7896012. [DOI] [PubMed] [Google Scholar]
  48. Young J. B. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int J Cardiol. 1994 Feb;43(2):151–163. doi: 10.1016/0167-5273(94)90004-3. [DOI] [PubMed] [Google Scholar]
  49. Zetter B. R. Assay of capillary endothelial cell migration. Methods Enzymol. 1987;147:135–144. doi: 10.1016/0076-6879(87)47104-8. [DOI] [PubMed] [Google Scholar]
  50. Zusman R. M. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis. 1987 Jul;10(1 Suppl 1):13–23. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES